Emerging Trends in India's Clinical Laboratory Sector: Balancing Scale and Speciality Testing

India's diagnostic services market is projected to grow at about 12% a year over the next five years, reaching US $15 to 16 billion by FY30. Growth is expected to be driven mainly by volumes, yet advanced testing is expanding too. A double-digit revenue growth in genomic testing, and molecular diagnostics is projected to be one of the fastest-growing segments of the in vitro diagnostics (IVD) market through 2031. That tension between volume and complexity makes India a useful case study in how a fast-growing market manages cost, capacity, and capability at once.

The scale story

CareEdge reports a highly fragmented market, with organised chains accounting for approximately 20 to 25% of the total and more than 130,000 laboratories nationwide. Chains are consolidating and expanding into tier 2, 3, and 4 towns, which the report expects to contribute significantly to growth. 

Several factors sit behind this growth:

• Preventive care. CareEdge links that wellness and preventive services revenue for those chains grew at over 25% a year in the four years to FY25.

   

• Urban concentration. Urban markets generate over 70% of diagnostic revenue, according to CareEdge, and the World Bank estimates India's urban population share at about 36% in 2025.

• Cost pressure. Revenue per test fell from Rs 233 in FY21 to Rs 187 in FY25, reflecting competition.

For suppliers, rising volumes and falling revenue per test may increase demand for efficient, reliable equipment, as CareEdge forecasts chains to rely on efficiency to sustain profitability.

The rise of specialty testing

Alongside routine volume, some laboratories are building specialty capability. Leading chains are investing heavily in genomic testing, which has enabled a superior product mix and higher margins. 

As laboratories expand their molecular testing capabilities, some are adopting next-generation sequencing (NGS) to analyse multiple genetic targets in a single workflow. Mordor Intelligence projects molecular diagnostics to grow at about 12.04% a year through 2031, NGS at about 16%, and oncology diagnostics at about 14.08%, although these are market-research estimates.

This can change laboratories' equipment, staffing, and infrastructure requirements. 

Genomic testing needs substantial investment in equipment, software, and skilled talent, which creates barriers for smaller players. 

Additionally, cold-chain gaps hold back molecular and immunoassay expansion, and that software and services are its fastest-growing product category, at about 15% a year.

The market may also split by price point. Mordor Intelligence reports that multinational manufacturers supply sequencing and high-end PCR systems, while domestic makers focus on low-cost rapid kits and mid-range biochemistry analysers. 

For suppliers of laboratory equipment and instruments, that may create demand at different price points and support levels.

Quality, standards, and compliance

As testing becomes more varied, accreditation may become a stronger point of difference. The National Accreditation Board for Testing and Calibration Laboratories (NABL) accredits medical laboratories against ISO 15189, the international standard for quality and competence in medical laboratories. 

Insurers are tightening quality criteria, which pushes smaller centres towards accreditation or partnerships. On 14 October 2025, NABL announced that accredited medical laboratories will receive 15% higher rates than non-accredited ones under the Central Government Health Scheme, a differential that applies to that scheme only.

Performance also depends on more than instrument specifications. Environmental conditions can affect measurement stability, so laboratories need controls and records showing that testing conditions stay within acceptable limits. This Analitika Expo guide to equipment and compliance in environmental testing explores the same principle.

Speciality testing can raise the compliance bar further. India's device regulator, the Central Drugs Standard Control Organisation (CDSCO), regulates IVDs under the Medical Devices Rules, 2017, including approval of clinical performance evaluation for new devices. 

For laboratories, the Ministry of Health and Family Welfare lists 12 states, plus all Union Territories except Delhi, as having adopted the Clinical Establishments Act, so registration requirements may vary by location.

Wider Implications

India's experience is a useful example rather than a universal template. The World Health Organization (WHO) describes diagnosis as the weakest link in the care cascade, particularly in primary care in low- and middle-income countries, many of which lack an integrated network of laboratories. The balance between routine testing and specialist diagnostics is a challenge that may resonate with laboratories in other markets, and choices around equipment, standards, and skills may follow similar lines.

Explore laboratory technologies at Analitika Expo

Analitika Expo brings together manufacturers, suppliers, distributors, laboratory specialists, researchers, and end users from Russia and across the wider CIS region. It takes place from 21 to 23 April 2027 at Crocus Expo, Pavilion 3, Hall 14, Moscow, and is organised by ITE Group.

To put your products in front of laboratory-sector buyers, submit an Analitika exhibit enquiry. 

For laboratory professionals looking to source new technologies, compare solutions, and connect with suppliers, register here to connect with manufacturers and suppliers and explore solutions for your laboratory needs.